INTRODUCTION
Cell based therapies for the repair of articular cartilage injuries are being pursued due to poor self-repair and limited efficacy of pharmacologic therapies. Adult, bone-marrow derived mesenchymal stem cells (MSCs) are a stem cell source for autologous cell transplantation to musculoskeletal tissues with good proliferation and chondrogenic differentiation potential. Despite the early promise of cartilage repair with naïve MSC implantation, evaluation in large animal models does not strongly support clinical use.

Homing of stem cells in response to local chemokine production and capillary fragility has been shown for bone injury, but is not nearly as clear in cartilage damage or progression of arthritis. Anecdotal evidence and clinical experience suggests that intra-articular injection of autologous bone marrow derived mesenchymal stem cells (MSCs) is an effective treatment for joint injury where more routine treatment protocols have failed.(1) Clinical efficacy may be due to focal localization of injected MSCs into articular cartilage defects, or potentially remote formation of synovial niches that enhance joint repair by synovial trophic factor elaboration or anti-inflammatory effects at the capsular and synovial level.

We hypothesized that autologous bone marrow derived mesenchymal stem cells (MSCs) would engraft to abnormal cartilage in OA joints but not in normal joints following intra-articular injection.

METHODS
Twenty-nine joints from 10 skeletally mature (median age, 4.5 years; range, 2-10 years) Thoroughbred or Thoroughbred cross horses were characterized as normal (noOA) or abnormal (OA) through clinical, lameness and radiographic examination. Bone marrow MSCs were isolated through tissue culture plastic adherence. Second passage autologous MSCs (Qdot® labeled for fetlocks and 5x10^6 for femoropatellar joints) were labeled with fluorescent nanoparticles (Quantum® dots; Qdot®) or left unlabeled (7 joints), and then injected to 17 noOA and 12 OA joints. Three ml of modified Eagles’ medium (MEM) and 5 ml MEM were used as a carrier solution for metacarpophalangeal and femoropatellar injection, respectively. Joints (cartilage, synovium, osteochondral) were collected 1 week after MSC injection for frozen and formalin fixed histologic preparations and evaluated for the presence of fluorescently labeled cells and tissue architecture. Synovial fluid analysis included fluorescent evaluation of cytopsin for the presence of fluorescent labeled cells and complete synovial analysis.

Twelve joints from Thoroughbreds (n=6; median age, 5 years; range, 3-7 years) with a similar distribution of OA and noOA fetlocks and stifles were injected with the same volume of carrier solution (MEM) injected joints versus MSC injected joints. Of the MSC injected joints, only injected with unlabeled MSCs and Qdot® labeled MSCs, suggesting that MSCs may engraft to synovial tissue. Mild, joint flares were common after intra-articular MSC injection. This was surprising given the relatively low dose of MSCs used. In a caprine stifle model of OA, a much larger cell dose (10x10^6 cells) was used without evidence of joint reaction.(2) These cells were suspended in hyaluronan rather than MEM. It seems unlikely that the addition of HA, rather than MEM, would reduce the joint reaction, given that clinical flares seem relatively common when HA is injected without steroid combination. We elected to use MEM rather than HA, in an effort to reduce the likelihood of post injection joint flares. Additionally, compared to joint flares in clinical patients, flares were mild with transient lameness and effusion that were easily distinguished from synovial sepsis. Although the flares were mild and self-limiting, this joint reaction is concerning, and additional experiments for a dose response test as well as characterization of the flare is warranted.

There were no differences in synovial cytology parameters for joints injected with unlabeled MSCs and Qdot® labeled MSCs, suggesting that Qdot® labeling is safe for intra-articular cell tracking. When comparing synovial cytology between OA and noOA injected joints (both labeled and unlabeled cells) there was a significant reduction of TNCC for OA joints compared to noOA joints. This may be a result of the immune modulating ability of MSCs when placed within an inflamed environment.(3)

SIGNIFICANCE
If intra-articular injection of MSCs is effective in reducing joint disease, it may be through modification of synovial fluid constituents, inflammation, or cytokine profile, rather than direct cartilage repair.

References:

Acknowledgements: Study funded by private gifts to the laboratory.

**Table 1. Synovial fluid cytology (median; interquartile range) one week after bmMSC in modified Eagles’ medium (MEM) injection or MEM alone. Values that were significantly different (P≤0.05) are marked by an asterisk.**

<table>
<thead>
<tr>
<th></th>
<th>MSC joints only injected</th>
<th>MEM joints only injected</th>
<th>2-tailed p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total nucleated cell count cells/microl</strong></td>
<td>2,800</td>
<td>1,750-4,450</td>
<td>850</td>
</tr>
<tr>
<td><strong>Lymphocytes %</strong></td>
<td>32</td>
<td>19-47</td>
<td>34</td>
</tr>
<tr>
<td><strong>Macrophages %</strong></td>
<td>64</td>
<td>48-76</td>
<td>42</td>
</tr>
<tr>
<td><strong>Neutrophils %</strong></td>
<td>5</td>
<td>0-1.5</td>
<td>7</td>
</tr>
<tr>
<td><strong>Total protein g/dl</strong></td>
<td>&lt;2.5</td>
<td>&lt;2.5-3.15</td>
<td>2.5</td>
</tr>
</tbody>
</table>

**Figure 1. Synovium (A, B, C) and cartilage (D, E, F) from an OA fetlock (400x), displaying A & D) Qdot® labeled MSCs, B & E) Hoechst stained nuclei and C & F) merge.**

**FIGURE**

**TABLE**

**RESULTS**
Clinical findings following MSC injection included increased lameness (n=2; 4/5 AAEP grading scheme), and severe (11), moderate (3), and slight effusion (4). Synovial fluid abnormalities included elevated neutoled cell counts (median 2,800/ul; interquartile range 1,750-4,450/ul), consisting of large mononuclear cells and small lymphocytes (Table 1). There were no statistically significant differences in synovial fluid parameters between Qdot® labeled MSC and unlabeled MSC injected joints. Of the MSC injected joints, only injected with unlabeled MSCs and Qdot® labeled MSCs, suggesting that Qdot® labeling was different when OA (median, 2,300 cells/ul; interquartile range, 1,420-2,875 cells/ul) and noOA joints (3,400 cells/ul; 2,400-5,150; 2-tailed p=0.04). Total nucleated cell count, percent macrophages and total protein were significantly different (lower) in MEM injected joints versus MSC injected joints (Table 1). Qdot® labeled MSCs were identified in synovial fluid from all Qdot® injected joints 1 week after injection.

QDot® labeled MSCs were found predominantly in the synovial membrane compared to control (p<0.0001; Figure 1). Adherence of labeled MSCs to cartilage was minimal and found in 17 of 97 cartilage sections. The proportion of positive sections from synovium and cartilage was not different between OA and normal joints (P=0.79).

Poster No. 1558  •  ORS 2012 Annual Meeting